Integration of transcriptomics, proteomics, metabolomics and systems pharmacology data to reveal the therapeutic mechanism underlying Chinese herbal Bufei Yishen formula for the treatment of chronic obstructive pulmonary disease

Zhao,Peng; Li,Jiansheng; Yang,Liping; Li,Ya; Tian,Yange; Li,Suyun

doi:10.3892/mmr.2018.8480

Integration of transcriptomics, proteomics, metabolomics and systems pharmacology data to reveal the therapeutic mechanism underlying Chinese herbal Bufei Yishen formula for the treatment of chronic obstructive pulmonary disease

Authors:
- Peng Zhao
- Jiansheng Li
- Liping Yang
- Ya Li
- Yange Tian
- Suyun Li
View Affiliations

Affiliations: Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Henan University of Chinese Medicine, Zhengzhou, Henan 450046, P.R. China, Collaborative Innovation Center for Respiratory Disease Diagnosis and Treatment and Chinese Medicine Development of Henan Province, Henan University of Chinese Medicine, Zhengzhou, Henan 450046, P.R. China
Published online on: January 25, 2018 https://doi.org/10.3892/mmr.2018.8480
Pages: 5247-5257
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bufei Yishen formula (BYF) is a traditional Chinese medicine formula, which has long been used as a therapeutic agent for the treatment of chronic obstructive pulmonary disease (COPD). Systems pharmacology has previously been used to identify the potential targets of BYF, and an experimental study has demonstrated that BYF is able to prevent COPD. In addition, the transcriptomic and metabolomic profiles of lung tissues from rats with COPD and BYF‑treated rats have been characterized. The present study aimed to determine the therapeutic mechanisms underlying the effects of BYF on COPD treatment by integrating transcriptomics, proteomics and metabolomics, together with systems pharmacology datasets. Initially, the proteomic profiles of rats with COPD and BYF‑treated rats were analyzed. Subsequently, pathway and network analyses were conducted to integrate three‑omics data; the results demonstrated that the genes, proteins and metabolites were predominantly associated with oxidoreductase activity, antioxidant activity, focal adhesion and lipid metabolism. Finally, a comprehensive analysis of systems pharmacology, transcriptomic, proteomic and metabolomic datasets was performed, and numerous genes, proteins and metabolites were found to be regulated in BYF‑treated rats; the potential target proteins of BYF were involved in lipid metabolism, inflammatory response, oxidative stress and focal adhesion. In conclusion, BYF exerted beneficial effects against COPD, potentially by modulating lipid metabolism, the inflammatory response, oxidative stress and cell junction pathways at the system level.

View Figures

View References

1	Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease GOLD executive summary. Am J Respir Crit Care Med. 187:347–365. 2013. View Article : Google Scholar : PubMed/NCBI
2	Beran D, Zar HJ, Perrin C, Menezes AM and Burney P; Forum of International Respiratory Societies working group collaboration, : Burden of asthma and chronic obstructive pulmonary disease and access to essential medicines in low-income and middle-income countries. Lancet Resp Med. 3:159–170. 2015. View Article : Google Scholar
3	Gan WQ, Man SF, Senthilselvan A and Sin DD: Association between chronic obstructive pulmonary disease and systemic inflammation: A systematic review and a meta-analysis. Thorax. 59:574–580. 2004. View Article : Google Scholar : PubMed/NCBI
4	Li SY, Li JS, Wang MH, Xie Y, Yu XQ, Sun ZK, Ma LJ, Zhang W, Zhang HL, Cao F and Pan YC: Effects of comprehensive therapy based on traditional Chinese medicine patterns in stable chronic obstructive pulmonary disease: A four-center, open-label, randomized, controlled study. BMC Complement Altern Med. 12:1972012. View Article : Google Scholar : PubMed/NCBI
5	Li J, Zhao P, Li Y, Tian Y and Wang Y: Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease. Sci Rep. 5:152902015. View Article : Google Scholar : PubMed/NCBI
6	Su G, Burant CF, Beecher CW, Athey BD and Meng F: Integrated metabolome and transcriptome analysis of the NCI60 dataset. BMC Bioinformatics. 12 Suppl 1:S362011. View Article : Google Scholar : PubMed/NCBI
7	Vogel C and Marcotte EM: Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 13:227–232. 2012. View Article : Google Scholar : PubMed/NCBI
8	Tan KC, Ipcho SV, Trengove RD, Oliver RP and Solomon PS: Assessing the impact of transcriptomics, proteomics and metabolomics on fungal phytopathology. Mol Plant Pathol. 10:703–715. 2009. View Article : Google Scholar : PubMed/NCBI
9	Wilmes A, Limonciel A, Aschauer L, Moenks K, Bielow C, Leonard MO, Hamon J, Carpi D, Ruzek S, Handler A, et al: Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. J Proteomics. 79:180–194. 2013. View Article : Google Scholar : PubMed/NCBI
10	Meierhofer D, Weidner C and Sauer S: Integrative analysis of transcriptomics, proteomics, and metabolomics data of white adipose and liver tissue of high-fat diet and rosiglitazone-treated insulin-resistant mice identified pathway alterations and molecular hubs. J Proteome Res. 13:5592–5602. 2014. View Article : Google Scholar : PubMed/NCBI
11	Li J, Yang L, Yao Q, Li Y, Tian Y, Li S, Jiang S, Wang Y, Li X and Guo Z: Effects and mechanism of bufei yishen formula in a rat chronic obstructive pulmonary disease model. Evid Based Complement Alternat Med. 2014:3819762014. View Article : Google Scholar : PubMed/NCBI
12	Yang LP, Li JS, Li Y, Tian Y, Li S, Jiang S, Wang Y and Song X: Identification of metabolites and metabolic pathways related to treatment with Bufei Yishen formula in a Rat COPD model using HPLC Q-TOF/MS. Evid-Based Complement Alternat Med. 2015:9567502015. View Article : Google Scholar : PubMed/NCBI
13	Li Y, Li SY, Li JS, Deng L, Tian YG, Jiang SL, Wang Y and Wang YY: A rat model for stable chronic obstructive pulmonary disease induced by cigarette smoke inhalation and repetitive bacterial infection. Biol Pharm Bull. 35:1752–1760. 2012. View Article : Google Scholar : PubMed/NCBI
14	Maere S, Heymans K and Kuiper M: BiNGO: A Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics. 21:3448–3449. 2005. View Article : Google Scholar : PubMed/NCBI
15	Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WH, Pagès F, Trajanoski Z and Galon J: ClueGO: A Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 25:1091–1093. 2009. View Article : Google Scholar : PubMed/NCBI
16	Karnovsky A, Weymouth T, Hull T, Tarcea VG, Scardoni G, Laudanna C, Sartor MA, Stringer KA, Jagadish HV, Burant C, et al: Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and gene expression data. Bioinformatics. 28:373–380. 2012. View Article : Google Scholar : PubMed/NCBI
17	Santus P, Sola A, Carlucci P, Fumagalli F, Di Gennaro A, Mondoni M, Carnini C, Centanni S and Sala A: Lipid peroxidation and 5-lipoxygenase activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 171:838–843. 2005. View Article : Google Scholar : PubMed/NCBI
18	Tulah AS, Parker SG, Moffatt MF, Wardlaw AJ, Connolly MJ and Sayers I: The role of ALOX5AP, LTA4H and LTB4R polymorphisms in determining baseline lung function and COPD susceptibility in UK smokers. BMC Med Genet. 12:1732011. View Article : Google Scholar : PubMed/NCBI
19	Barnes PJ: Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 35:71–86. 2014. View Article : Google Scholar : PubMed/NCBI
20	Sunnetcioglu A, Alp HH, Sertogullarindan B, Balaharoglu R and Gunbatar H: Evaluation of oxidative damage and antioxidant mechanisms in COPD, lung cancer, and obstructive sleep apnea syndrome. Respir Care. 61:205–211. 2016. View Article : Google Scholar : PubMed/NCBI
21	Lakhdar R, Denden S, Mouhamed MH, Chalgoum A, Leban N, Knani J, Lefranc G, Miled A, Ben Chibani J and Khelil AH: Correlation of EPHX1, GSTP1, GSTM1, and GSTT1 genetic polymorphisms with antioxidative stress markers in chronic obstructive pulmonary disease. Exp Lung Res. 37:195–204. 2011. View Article : Google Scholar : PubMed/NCBI
22	Escribano A, Amor M, Pastor S, Castillo S, Sanz F, Codoñer-Franch P and Dasí F: Decreased glutathione and low catalase activity contribute to oxidative stress in children with α-1 antitrypsin deficiency. Thorax. 70:82–83. 2015. View Article : Google Scholar : PubMed/NCBI
23	Rahman I and MacNee W: Antioxidant pharmacological therapies for COPD. Curr Opin Pharmacol. 12:256–265. 2012. View Article : Google Scholar : PubMed/NCBI
24	Harju T, Kaarteenaho-Wiik R, Sirvio R, Sirviö R, Pääkkö P, Crapo JD, Oury TD, Soini Y and Kinnula VL: Manganese superoxide dismutase is increased in the airways of smokers' lungs. Eur Respir J. 24:765–771. 2004. View Article : Google Scholar : PubMed/NCBI
25	Dong X, Liu Y, Du M, Wang Q, Yu CT and Fan X: P38 mitogen-activated protein kinase inhibition attenuates pulmonary inflammatory response in a rat cardiopulmonary bypass model. Eur J Cardiothorac Surg. 30:77–84. 2006. View Article : Google Scholar : PubMed/NCBI
26	Huang Y, Meng XM, Jiang GL, Yang YR, Liu J, Lv XW and Li J: Studies on mitogen-activated protein kinase signaling pathway in the alveolar macrophages of chronic bronchitis rats. Mol Cell Biochem. 400:97–105. 2015. View Article : Google Scholar : PubMed/NCBI
27	Kida Y, Kobayashi M, Suzuki T, Takeshita A, Okamatsu Y, Hanazawa S, Yasui T and Hasegawa K: Interleukin-1 stimulates cytokines, prostaglandin E2 and matrix metalloproteinase-1 production via activation of MAPK/AP-1 and NF-kappaB in human gingival fibroblasts. Cytokine. 29:159–168. 2005. View Article : Google Scholar : PubMed/NCBI